The first WHO Global report on diabetes demonstrates that the number of adults living with diabetes has almost quadrupled since 1980 to 422 million adults. Factors driving this dramatic rise, which is largely on account of type 2 diabetes, include overweight and obesity. The new report calls upon governments to ensure that people are able to make healthy choices and that health systems are able to diagnose, treat and care for people with diabetes.
“Diabetes type 1 is very different from your standard disease. Insulin requirements vary greatly from one day to another and there is no way patients can know what they need,” Roman Hovorka, Professor at the University of Cambridge, explained to me during an interview. His research group is working on the development of an algorithm that can accurately predict insulin requirements for a specific patient at any moment.
Dunn collected his presentations in a 1961 book, “High-Level Wellness,” but it would take another decade for his work to resonate with a committed group of followers. An early acolyte was John W. Travis, who picked up Dunn’s book in 1972 from a $2 clearance table at the bookstore of Johns Hopkins Medical School, where he was enrolled in a preventive-medicine residency program. Travis didn’t think much of Dunn’s buzzword at first. “I thought the word wellness was stupid, and it would never catch on,” he recently told me. But Travis was enamored with the way Dunn presented his ideas, and he put those ideas into action — and reluctantly embraced the word itself — when he opened the Wellness Resource Center in Mill Valley, Calif., in November 1975. The center promoted self-directed approaches to well-being as an alternative to the traditional illness-oriented care of physicians.
Body blasting was just one of the hundreds of classes, sessions, panels, talks, and silent dance parties at the inaugural Wellspring wellness festival. Last month some 2,000 mannequin-shaped people floated into Palm Springs, California, for what advertisements promised to be “a first-of-its-kind wellness festival, that will feature over 200 transformational workshops, treatments, and fitness across multiple categories.” The goal was to “provide seekers the tools to learn and take action in real time for a healthier mind in a relational platform.” (Relational platform was a new term to me, but people seemed less than pleased when I used the word conference.)
Poxel (PP:POXEL) is a French pharmaceutical company that recently received $30.1 million in post-IPO equity in 2016. The company has developed an orally active medication called Imeglimin, which targets all three organs and body systems that are affected by diabetes simultaneously: the pancreas, liver, and muscles. The drug is currently undergoing phase 3 clinical work in Japan, and will commence phase 3 trials in the European Union and the United States that will be completed by 2019. The company is also concurrently working on several other pharmaceutical agents in various stages of the development pipeline.
Diabetes is a disease in which your blood glucose, or blood sugar, levels are too high. Glucose comes from the foods you eat. Insulin is a hormone that helps the glucose get into your cells to give them energy. With type 1 diabetes, your body does not make insulin. With type 2 diabetes, the more common type, your body does not make or use insulin well. Without enough insulin, the glucose stays in your blood. You can also have prediabetes. This means that your blood sugar is higher than normal but not high enough to be called diabetes. Having prediabetes puts you at a higher risk of getting type 2 diabetes.